Patients with statin intolerance should first consider evidence-based alternatives like ezetimibe, bempedoic acid, PCSK9 inhibitors, or inclisiran before considering GLP-1 therapy primarily for lipid management
Understanding these factors is useful for patients who may be considering participation in a trial or who wish to discuss emerging therapies with their healthcare provider
Sam Sukkar, MD, The Clinic for Plastic Surgery
Phase 3 TRIUMPH adds an intermediate 6 mg step and treats 4 mg, 9 mg, and 12 mg as target maintenance doses depending on the trial arm
Common side effects may include nausea, bloating, or mild diarrhea, which often improve over time
Still, there is no universal day when side effects begin or a guarantee that they disappear by month 3